Perreault, S., Larouche, V., Tabori, U., Hawkin, C., Lippé, S., Ellezam, B., Décarie, J.-C., Théoret, Y., Métras, M.-É., Sultan, S., Cantin, É., Routhier, M.-È., Caru, M., Legault, G., Bouffet, É., Lafay-Cousin, L., Hukin, J., Erker, C., & Jabado, N. (2019). A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. BMC Cancer, 19(1), 1250. doi:10.1186/s12885-019-6442-2

This content is not available in the selected language.

This content has been updated on 27 July 2025 at 15h27.